MX2007011356A - Anticuerpos contra antigenos de candida. - Google Patents

Anticuerpos contra antigenos de candida.

Info

Publication number
MX2007011356A
MX2007011356A MX2007011356A MX2007011356A MX2007011356A MX 2007011356 A MX2007011356 A MX 2007011356A MX 2007011356 A MX2007011356 A MX 2007011356A MX 2007011356 A MX2007011356 A MX 2007011356A MX 2007011356 A MX2007011356 A MX 2007011356A
Authority
MX
Mexico
Prior art keywords
antibodies against
against candida
candida antigens
domain antibodies
antigens
Prior art date
Application number
MX2007011356A
Other languages
English (en)
Inventor
Antonio Cassone
Flavia De Bernardis
Steven Grant
Haiqun Liu
Original Assignee
Domantis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0505489A external-priority patent/GB0505489D0/en
Priority claimed from GBGB0519883.3A external-priority patent/GB0519883D0/en
Application filed by Domantis Ltd filed Critical Domantis Ltd
Publication of MX2007011356A publication Critical patent/MX2007011356A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/14—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporcionan anticuerpos de dominio. En particular, anticuerpos de dominio (dAbs) que reconocen rasgos de virulencia de Candida spp. y que confieren una proteccion pasiva contra candidiasis.
MX2007011356A 2005-03-18 2006-03-10 Anticuerpos contra antigenos de candida. MX2007011356A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0505489A GB0505489D0 (en) 2005-03-18 2005-03-18 Antibodies
GBGB0519883.3A GB0519883D0 (en) 2005-09-29 2005-09-29 Antibodies
PCT/GB2006/000843 WO2006097689A2 (en) 2005-03-18 2006-03-10 Antibodies against candida antigens

Publications (1)

Publication Number Publication Date
MX2007011356A true MX2007011356A (es) 2008-03-10

Family

ID=36808786

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007011356A MX2007011356A (es) 2005-03-18 2006-03-10 Anticuerpos contra antigenos de candida.

Country Status (12)

Country Link
US (1) US8092800B2 (es)
EP (1) EP1863845A2 (es)
JP (1) JP2008533115A (es)
KR (1) KR20080003351A (es)
AU (1) AU2006224438A1 (es)
CA (1) CA2601115A1 (es)
EA (1) EA200701766A1 (es)
IL (1) IL185781A0 (es)
MA (1) MA29394B1 (es)
MX (1) MX2007011356A (es)
NO (1) NO20074616L (es)
WO (1) WO2006097689A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8092800B2 (en) 2005-03-18 2012-01-10 Istituto Superiore Di Sanita Antibodies against Candida antigens
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
US20090081196A1 (en) * 2007-02-16 2009-03-26 Istituto Superiore Di Sanita Medicaments for fungal infections
KR20110071139A (ko) * 2008-10-21 2011-06-28 도만티스 리미티드 Ｄｃ­ｓｉｇｎ에 대한 결합 특이성을 갖는 리간드
WO2011035205A2 (en) 2009-09-18 2011-03-24 Calmune Corporation Antibodies against candida, collections thereof and methods of use
WO2012145666A1 (en) * 2011-04-21 2012-10-26 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Peptide and conjugate vaccines for fungal infections
CN107663239A (zh) * 2016-12-28 2018-02-06 天津天锐生物科技有限公司 一种识别hla‑a2/nlvpmvatv的单域抗体
CN109336976B (zh) * 2018-09-27 2021-04-02 暨南大学 抗人egfr的纳米抗体及其应用
WO2020130838A2 (en) * 2018-12-21 2020-06-25 Qvq Holding B.V. Antibodies for preventing or treating candidiasis
CN112646035B (zh) * 2020-12-25 2022-06-24 暨南大学 Egfr的亲和力成熟结合蛋白及应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7419781B1 (en) 1999-02-01 2008-09-02 Planton Gmbh Human antibiotic proteins
US7521053B2 (en) * 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
KR20040094705A (ko) 2002-02-21 2004-11-10 듀크 유니버시티 자가면역질환에 대한 시약 및 치료 방법
EP2366718A3 (en) * 2002-06-28 2012-05-02 Domantis Limited Ligand
CA2505316C (en) * 2002-11-08 2014-08-05 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
CA2512545C (en) * 2003-01-10 2015-06-30 Karen Silence Recombinant vhh single domain antibody from camelidae against von willebrand factor (vwf)
EP1603948A1 (en) * 2003-03-14 2005-12-14 Pharmacia Corporation Antibodies to igf-i receptor for the treatment of cancers
CN1845938B (zh) 2003-06-30 2010-05-26 杜门蒂斯有限公司 多肽
WO2005097202A2 (en) 2004-04-06 2005-10-20 Affibody Ab Use of serum albumin binding peptides conjugates for the preparation of a medicament
US7563443B2 (en) * 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
US8092800B2 (en) 2005-03-18 2012-01-10 Istituto Superiore Di Sanita Antibodies against Candida antigens
GB0624500D0 (en) 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections

Also Published As

Publication number Publication date
KR20080003351A (ko) 2008-01-07
CA2601115A1 (en) 2006-09-21
EP1863845A2 (en) 2007-12-12
NO20074616L (no) 2007-11-27
US8092800B2 (en) 2012-01-10
AU2006224438A1 (en) 2006-09-21
IL185781A0 (en) 2008-01-06
JP2008533115A (ja) 2008-08-21
MA29394B1 (fr) 2008-04-01
WO2006097689A2 (en) 2006-09-21
US20080193450A1 (en) 2008-08-14
EA200701766A1 (ru) 2008-04-28
WO2006097689A3 (en) 2007-03-15

Similar Documents

Publication Publication Date Title
MX2007011356A (es) Anticuerpos contra antigenos de candida.
TW200732349A (en) Anti-OX40L antibodies and methods using same
MY148635A (en) Anti-tat226 antibodies and immunoconjugates
GB0711230D0 (en) Devices and methods for tracking,locating and providing protection to individuals
WO2007136893A3 (en) Anti-fgf19 antibodies and methods using same
TW200740458A (en) Vaccination against dengue virus infection
WO2007140371A3 (en) Antibodies and immunoconjugates and uses therefor
SG196835A1 (en) Human anti-b7rp1 neutralizing antibodies
WO2010129609A3 (en) Antibodies and methods of use thereof
WO2009120893A3 (en) Polypeptide-polymer conjugates and methods of use thereof
WO2008039390A3 (en) Compositions and methods for chitosan enhanced immune response
WO2008002810A3 (en) Methods and apparatus for location based services in wireless networks
MA33551B1 (fr) Anticorps anti-egfl1 humanises, et procedes d'utilisation correspondants
ZA200711073B (en) Anti-MCP-1 antibodies, compositions, methods and uses
WO2007127350A3 (en) Method and system for user-designed application deployment
PH12013502194A1 (en) Antibodies to egfl7 and methods for their use
TW200704105A (en) User authentication using personal objects
WO2007127506A8 (en) Anti-ephrinb2 antibodies and methods using same
WO2008036317A3 (en) Systems and methods for pathogen detection and response
WO2007146199A3 (en) Assessment of functional status
EP1843774A4 (en) EXTRACTS FROM PULSATILLA SPP. WITH EFFECT ON BRAIN FUNCTION
EP2061326A4 (en) COMPOSITION BASED ON BACILLUS SPP. AND SIMILAR SPECIES AND ITS USE IN THE FIGHT AGAINST PESTS
WO2008054484A3 (en) Compositions, materials incorporating the compositions, and methods of using the compositions and materials
PL1909830T3 (pl) Ograniczenie oddziaływania pomiędzy olejem w adiuwancie a środkiem powierzchniowo czynnym w antygenie
GT200700016S (es) Envase

Legal Events

Date Code Title Description
FA Abandonment or withdrawal